

On the prevalence of *KRAS* mutations in GISTs

Riccardo Ricci · Angelo Paolo Dei Tos · Guido Rindi

Received: 30 September 2013 / Accepted: 2 October 2013 / Published online: 19 October 2013
© Springer-Verlag Berlin Heidelberg 2013

Dear Editor,

In our commentary entitled “GISTogram: a graphic presentation of the growing GIST complexity,” recently published in *Virchows Archiv* [1], on the basis of an extrapolation from a naïve GIST cohort from Ticino, Switzerland [2], we proposed a possible 4 % prevalence of *KRAS* mutations in GISTs. A recent paper by Lasota et al. reported about the absence of *KRAS* mutations in a large cohort of GISTs ($n=514$) [3] which, to the best of our knowledge, constitutes by itself about 60 % of cases so far studied for this molecular alteration [4–7]. Thus, considering the cumulative evidence produced so far, the actual possible prevalence of *KRAS* mutations in GISTs seems much lower than the one we hypothesized, possibly approaching 0.3 %.

References

1. Ricci R, Dei Tos AP, Rindi G (2013) GISTogram: a graphic presentation of the growing GIST complexity. *Virchows Arch* 463:481–487
2. Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, Saletti P, Mazzucchelli L, Pilotti S, Pierotti MA, Tamborini E, Greco A, Frattini M (2012) *KRAS* and *BRAF* mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. *Clin Cancer Res* 18:1769–1776
3. Lasota J, Xi L, Coates T, Dennis R, Evtuomwan MO, Wang ZF, Raffeld M, Miettinen M (2013) No *KRAS* mutations found in gastrointestinal stromal tumors (GISTs): molecular genetic study of 514 cases. *Mod Pathol*. doi:10.1038/modpathol.2013.89
4. Agaimy A, Terracciano LM, Dimhofer S, Tornillo L, Foerster A, Hartmann A, Bihl MP (2009) V600E *BRAF* mutations are alternative early molecular events in a subset of *KIT/PDGFR* wild-type gastrointestinal stromal tumours. *J Clin Pathol* 62:613–616
5. Martinho O, Gouveia A, Viana-Pereira M, Silva P, Pimenta A, Reis RM, Lopes JM (2009) Low frequency of MAP kinase pathway alterations in *KIT* and *PDGFR* wild-type GISTs. *Histopathology* 55:53–62
6. Daniels M, Lurkin I, Pauli R, Erböstösser E, Hildebrandt U, Hellwig K, Zschille U, Lüders P, Krüger G, Knolle J, Stengel B, Prall F, Hertel K, Lobeck H, Popp B, Theissig F, Wünsch P, Zwarthoff E, Agaimy A, Schneider-Stock R (2011) Spectrum of *KIT/PDGFR/BRAF* mutations and phosphatidylinositol-3-kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). *Cancer Lett* 312:43–54
7. Origone P, Gargiulo S, Mastracci L, Ballestrero A, Battistuzzi L, Casella C, Comandini D, Cusano R, Dei Tos AP, Fiocca R, Garuti A, Ghiorzo P, Martinuzzi C, Toffolatti L, Liguria GIST Unit, Bianchi Scarrà G (2013) Molecular characterization of an Italian series of sporadic GISTs. *Gastric Cancer* 16:596–601

R. Ricci (✉) · G. Rindi
Department of Pathology, Università Cattolica de Sacro Cuore, Largo
A. Gemelli, 8, 00168 Rome, Italy
e-mail: riccardoricci@rm.unicatt.it

A. P. Dei Tos
Department of Pathology, Treviso Regional Hospital, Piazza
Ospedale 1, 31100 Treviso, Italy